Heron Withdraws 2026 Guidance as CINVANTI Patent Loss Clouds Outlook
HRTX is trading near its 52-week low of $0.303 (12% above the low).
Summary
Heron Therapeutics withdrew its full-year 2026 guidance for net product sales and Adjusted EBITDA, citing uncertainty from the CINVANTI patent invalidation and an ongoing strategic review. Q2 revenue came in at $37.7M, with ZYNRELEF contributing $11.1M and APONVIE $4.2M, while cash stood at $42.7M. This follows the June 2 federal court ruling that invalidated key CINVANTI patents, opening the door to generic competition and triggering a Nasdaq delisting notice. The guidance withdrawal signals management cannot forecast the business with confidence amid the patent appeal and strategic alternatives process. Watch for updates on the CINVANTI appeal and any outcome from the strategic review, which could include a sale or restructuring.
At the time of this announcement, HRTX was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.9M. The 52-week trading range was $0.30 to $1.58. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.